Your safety is our top priority.
study on epithalon's effects in test animals also included a clinical component that involved 12 volunteers taking the peptide and 8 volunteers given placebo
DOI: Saltzman RG, Jayaweera DT, Caceres LV, Tovar JA, Vidro-Casiano M, Karakeshishyan V, Soto J, Khan A, Mitrani RD, Schulman IH, Hare JM
Understanding the difference between pharmacological necessity and clinical strategy helps patients and providers make informed decisions about safely discontinuing tirzepatide while maintaining optimal health outcomes
Accessed 05/08/2022
Attend A&E or call 999 if you experience persistent vomiting preventing fluid intake, severe abdominal pain (especially radiating to the back), signs of dehydration, upper right abdominal pain with fever or jaundice, or inability to tolerate food or fluids for more than 24 hours